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ong before his meteoric rise to
a Nobel Prize at age 42 and to
the presidency of the Howard
Hughes Medical Institute (HHMI) a
decade later, Tom Cech was just
another guy working down the hall
from me. In the mid 1970s, our lives
intersected at the Massachusetts
Institute of Technology (MIT) when he
was a postdoc and I a graduate student.
I recall a lanky midwesterner, modest
and likeable, earnestly working on a
project that didn’t seem too exciting, or
certainly didn’t seem to be the stuff of
scientiﬁc breakthrough, prizes, or fame.
I took advantage of our brief shared
history to enlist Tom for an interview.
We set up a video conference: Tom,
nursing what appeared to be a green
bottle of Perrier at the HHMI
headquarters, and I, armed with a re-
heated cup of coffee in the pristine
conﬁnes of the HHMI conference
center at the University of California
San Francisco. The video transmission
suffered from episodes of stutter and
delay, with Tom’s voice and image out
of sync, disconcertingly causing Tom to
look like a man on a lunar mission in
an Apollo spacecraft, rather than safely
ensconced in Chevy Chase.
We got the ball rolling with a bit of
reminiscing about our experience 30
years ago at MIT.
Jane Gitschier: When I came to MIT in
September of 1975, I recall being thrust
into an exhilarating atmosphere. The
ﬁrst seminar of the year, called
together hastily, was by Phil Sharp, who
had just returned from Cold Spring
Harbor to describe RNA splicing for
the ﬁrst time. One month later,
champagne was ﬂowing in the hallways
because David Baltimore was awarded a
Nobel Prize. It was something!
Tom Cech: I had the same experience.
We were in the old-fashioned biology
building, 16–56, but it was a very
exciting place. My benchmate [in Mary
Lou Pardue’s lab] was Joan Ruderman,
and Matt Scott and Al Spradling were
in the lab at the same time. It was a very
small lab, but half the people ended up
getting elected to the National
Academy of Sciences. There was a very
high level of scholarly interest, good
critical thinking, and a lot of
excitement about science.
Gitschier: I recall you studying psoralen
cross-linking. What were you really up
to?
Cech: I was looking for a way to freeze
nucleic acid structures in vivo, and
then to pull them out without
rearranging them. I was particularly
interested in alternative secondary
structures of DNA, cruciform
structures, and I was doing almost
exclusively electron microscopy. I did
that for a long time! I was trained in the
Cal Tech/Norm Davidson/Phil Sharp/
Ron Davis tradition of quantitative
DNA electron microscopy, so you
always had to measure hundreds of
molecules before you believed what you
were seeing in the EM [electron
microscope].
Most DNA molecules look very
boring because they are just a double
helix. But if it’s branched, or if it’s a
replication form or a Holliday junction
or some alternative form, it [psoralen
cross-linking] can be a useful tool. But
then John Hearst’s lab found that
information about where the
nucleosomes were located on the DNA
was also preserved because the regions
that were in the linkers between
nucleosomes were much more
accessible to cross-linking than the
regions wrapped around the histones.
I built a zapper. I bought a high-
intensity mercury vapor lamp, the kind
used in streetlights, and I set it all up
myself! I was amazed that no one got
killed because I never had any training.
I built this thing with the shield and the
switch and the temperature-controlled
reaction chamber. You don’t realize
how bright and hot these streetlights
are till you get one a foot away. There is
an immense ﬂux of light coming out of
there. And that’s the wavelength of
radiation that activates the psoralen
cross-linking. That thing may still be
there at MIT.
Gitschier: So you moved to Boulder,
left the cross-linking, and moved on to
ribosomal RNA genes.
Cech: The main thing I decided was to
do something completely different
when I started my faculty position.
Gitschier: That seems unusual; most
people capitalize on the progress
they’ve made as a postdoc.
Cech: I think it was a little less unusual
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chromatin structure of a transcription
unit. People could clone DNA by then,
but they couldn’t clone DNA with its
natural histone and nonhistone
proteins associated with it in the right
place. Tetrahymena had 10,000
identical copies of the ribosomal gene.
I thought that one could isolate the
gene in its chromatin state and look for
regulation of transcription. It was a ﬁne
idea—it never worked.
Gitschier: But fortunately, something
else worked!
Cech: But fortunately, the gene had an
intron, which it wasn’t even supposed
to have! As you mentioned, this was
right after Phil Sharp and Cold Spring
Harbor had discovered RNA splicing.
By the time I was an assistant professor,
there were 100 examples of eukaryotic
introns, but no information about
splicing mechanisms. In fact, people
were just starting to come to grips with
the fact that it was splicing rather than
some kind of transcriptional jumping.
Gitschier: I remember that debate.
Cech: There were several papers,
including one by Shirley Tilghman and
Phil Leder, showing that there was a
precursor RNA that was then processed
into spliced RNA, so it looked like
splicing was operating at the RNA level.
But there was only one lab, John
Abelson’s in Southern California,
studying yeast splicing, which had
much of a handle on splicing in vitro.
So when we found that the intron in
our ribosomal genes was being spliced,
there was a fork in the road. We could
either say, ‘‘We’re not funded to do
splicing research by the NIH [National
Institutes of Health]; we’re funded to do
transcriptional regulation, so let’s just
report that intron and leave that for
someone else to follow up,’’ or we could
follow this splicing angle. We tried to do
both for a while, but of course the
splicing became more interesting.
Gitschier: Tell me more about that
discovery.
Cech: It was during a period of about a
year when I was insisting that there had
to be a protein enzyme stuck to the
RNA that was doing the splicing, and
we were trying to shake it off so that we
could get back to studying the splicing
protein. Boiling the RNA, adding ionic
detergent, boiling in the presence of
detergents, adding proteases—all had
no effect. We were getting more and
more desperate!
As time went on, it seemed less and
less likely that there could be a protein,
but if we announced that the RNA was
self-splicing, no one was going to
believe us! So we then turned to
recombinant DNA, which we didn’t
know anything about, and we made an
artiﬁcial gene with a promoter and
puriﬁed it in E. coli [Escherichia Coli].
When RNA transcribed in vitro from
the artiﬁcial gene underwent splicing,
then we were convinced.
During that year, there was a slow
transition from thinking there was a
proteintothinkingtherecouldn’tbeone.
Bythetimewedidtheﬁnalexperiment,it
had to work without the protein because
there was no backup plan.
Gitschier: Have you had any other
‘‘eureka’’ moments?
Cech: We’ve been fortunate to have a
couple more, but they weren’t as
exciting to me because I was doing
those [splicing] experiments with my
own hands, together with Arthur Zaug
and Paula Grabowski. That is a special
kind of ‘‘eureka’’ moment.
Since then, we’ve had a couple of big
moments in the lab. One was ﬁnding
the catalytic subunit of telomerase,
something that had been predicted by
Liz Blackburn and Carol Greider as
early as 1985, when they described
telomerase and found the RNA subunit.
But ten years had gone by, and the
whole world and a couple of biotech
companies were searching for the
catalytic subunit, when a postdoc in my
lab, Joachim Lingner, puriﬁed the
catalytic subunit from euplotes. We
called it TERT telomerase for
‘‘telomerase reverse transcriptase.’’
And in 2001, Peter Baumann found a
protein that caps off the very ends of
human chromosomes; we called it
POT1 for ‘‘protection of telomeres.’’
We found it ﬁrst in ﬁssion yeast, and
did the genetics there.
The human genome project isgreat—
we do all this work in simple organisms,
and if you believe in evolution, you
believe these things are probably
widespread and can be found in the
human database. That was another very
exciting moment, again, because these
telomere-capping proteins had been
found 20 years earlier in ciliates, and
people had been wondering whether
the ciliates were special or whether all
eukaryotes would have them.
Gitschier: Were you disappointed that
these weren’t RNA molecules?
Cech: Well, it was exciting enough that
telomerase was half RNA.
Gitschier: Can you speak about how our
whole perspective has changed in the
last 20 years since the discovery of RNA
as a catalytic moiety?
Cech: There are so many areas in which
the RNA science has provided
excitement. The whole nature of the
ribosome, for example, and the work in
Harry Noller’s lab at UCSC [University
of California Santa Cruz]—where his
experiments indicated very strongly
that RNA in the ribosome was doing
more than just scaffolding key proteins,
and that the RNA was the important
entity for peptidyl transfer. That work
came to its culmination when Tom
Steitz and Peter Moore determined the
crystal structure of the large subunit of
the ribosome, showing that at the
peptidyl transfer center, there was only
RNA.
But look back at Jacob and Monod’s
early thinking that the lac repressor
might be an RNA molecule. Once the
lac repressor was proven to be a
protein, people got all focused on gene
expression being regulated by proteins.
But if they had been looking in bacillus,
rather than in E. coli, they would have
found riboswitches built into
transcripts that bind small-molecule
metabolites and control transcriptional
termination or translation. So the old
Jacob/Monod model was actually right,
but for a different branch of bacteria.
And of course, you can’t even turn
around without seeing RNAi [RNA
interference] and siRNA [small
interfering RNA] all over the place. So
chances are there are still a lot of RNA-
level functions to be discovered in
complex genomes.
Gitschier: In an interview, you said you
were a proliﬁc writer as a younger man.
What kind of writing did you enjoy, and
do you still write?
Cech: I don’t know that I ever enjoyed
writing—writing is painful!
I started with a fourth grade teacher
who made us write essays till our hands
felt like they would fall off. I did a lot of
writingatGrinnellCollege—humanities
courses, great books courses, and a
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learning to write a good argument and
support a point of view in the
humanities really helps your scientiﬁc
writing. Scientiﬁc writing is particularly
difﬁcult, and you need all the help you
can get. I’ve never written ﬁction or
poetry or anything really interesting.
Gitschier: Do you ever think about
attempting that?
Cech: I do think often about writing a
book about my own experience in
science. I like these books that some of
my colleagues have written because
they humanize the process, and they
show how twisted the path to scientiﬁc
knowledge is. I think there is so little
understanding in the general public
about the life of a scientist or the
scientiﬁc process, and especially about
the intense skepticism that we bring to
everything we hear about or to even the
discoveries in our own lab. I think if
more of the problems in politics,
governmental policy, and international
affairs were approached with more of a
scientiﬁc attitude, we would all be
better off.
Gitschier: I would agree with you, and I
would encourage you to follow through
on that. What have been some of your
favorites?
Cech: I re-read Watson’s Double Helix
recently. It’s really well written: the
excitement, the uncertainty, the
despair and disappointment, and the
exhilaration. That’s probably the best
example of a scientist giving an account
of a portion of his own work.
Gitschier: You love doing research, and
you’re obviously so good at it, so why
did you take the job of president of the
HHMI?
Cech: After the Nobel Prize, I had a
great decade of additional work and a
big lab of 25 or more students and
postdocs, who are now professors at
good places around the country. And I
did a lot of teaching; for instance, I
insisted on teaching general chemistry
for freshman for six years.
But I felt I was making an impact on
only a local level, and I had a need to
make an impact more nationally. So I
started to serve on some scientiﬁc
advisory boards. It was useful; however,
I’d go there and have a great
interaction, but then I’d leave and the
people [I was advising] were still stuck
there. If you really want to nurture
something, you have to be there when
the initial excitement subsides.
So I thought I would consider
moving into a leadership position, but
promised my family I would wait till my
daughters ﬁnished high school. Then
the Hughes position came along and
that seemed so special, and one that
doesn’t come along very often. It was
the idea of having an impact on the
educational programs that was the big
driver for me. The investigator
program was so well run that there
wasn’t so much of a challenge.
Gitschier: Max Cowan [former vice
president of the HHMI] told me that
you were one of his top choices for the
HHMI presidency, speciﬁcally because
of your keen commitment to teaching.
Cech: Is that right? Well, thank you! He
never shared that with me, although we
always had a very good relationship.
We’ve evaluated all the educational
programs; we’ve discontinued a number
ofthem,startednewones,andmassaged
others. The role of a nonproﬁt is to do
something different from the federal
government, including things that have
some risk, because you want to try
something that can have a huge impact.
But then you have to have the discipline
and strength to discontinue things if
they aren’t successful.
Every time we’ve discontinued a
program, there is a ﬁrestorm of outrage
in the community, and I get accosted
personally and get a lot of angry letters,
but that’s part of being in leadership—
to evaluate and get good advice from
the best people you can ﬁnd, including
the trustees, and then to just do it.
Gitschier: So, how do you like the job?
Cech: There are large parts that I ﬁnd
to be enjoyable, and there are also
signiﬁcant parts that I ﬁnd important
to be done well but which there’s not
much enjoyment in. You know, it’s
really wonderful being a university
professor!
Gitschier: I know!
Cech: There is tremendous amount of
freedom, and people don’t yell at you
very much either!
In this job, you make a lot of people
happy and a lot of people very
unhappy, and the people who you make
unhappy are sometimes gracious and
understanding, but sometimes they’ll
never forgive you. But you have a
process, and you have to take the
scientiﬁc review board advice
extremely seriously. And it’s also really
important for there to be turnover.
Gitschier: Now that you are at the helm
of the HHMI enterprise, you have a
special vantage point overlooking
biomedical research. What do you ﬁnd
the most interesting?
Cech: The most eye-opening for me has
been the neurosciences, probably
because it’s the area where I was the
most ignorant, but also because it’s
extremely exciting to be probing the
cellular and molecular basis of
behavior, sensory perception, and
memory, and moving toward
understanding consciousness and
cognition. I ﬁnd the neuroscience talks
to be the most riveting.
The other area, also very far from my
upbringing, that I ﬁnd to be so gratifying
andsoimportantistranslationalmedical
research. People doing really high-
quality basic research stimulatedbywhat
they have seen in the clinic. It is really
exciting when one of the investigators
makesamousemodelthatrecapitulatesa
humandisease,treatsthemouse,andgets
an effect, and now is treating patients
and gets remediation of the disease.
Gitschier: So if you were going to start a
postdoc today, what would you choose?
Cech: I’d probably still be a boring
chemist because I personally love
thinking about the molecules. I do want
to be thinking about molecules that are
important for human health.
It h i n ky o uh a v et od ow h a ty o u r
passion is. My passion is to think about
nucleic acids folding up and interacting
with themselves, interacting with small
molecules,andinteractingwithproteins,
and also to think about biochemical
reactions, about how their speciﬁcity
and rate enhancement is generated. In
ten years, the stuff we’re doing will
probably be totally unfundable!
Gitschier: How long do you think you’ll
be staying with the HHMI?
Cech: I serve at the pleasure of the
trustees, and so far they’ve been
supportive. Things are still exciting. It’s
beenveryimportantformetohavebeen
able to continue some research because
it uses a completely different set of
neurons than administrative work.
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in research. You never get there—but
there are criteria by which you judge
how close you are. You’re always
criticizing yourself and criticizing your
colleagues, and they’re criticizing you.
And there is a test, very often, that you
can do to decide who’s right.
But in administrative work, it’s all
about empowering people, and there is
never any absolute truth, and you can
never fool yourself into thinking you’ve
made all the right decisions. They are
completely different jobs, and I enjoy
them both.
There is perceived value to Hughes
to have the leadership actively engaged
in science. The real question is what
will happen to my 30-year NIH grant
coming up for renewal next year. &
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